As of November 6, 2026, Dyne Therapeutics, Inc. is a publicly traded company (Nasdaq: DYN); its largest reported holder is T. Rowe Price, with 18.7% on Schedule 13G/A of May 15, 2026, then Janus Henderson (8.3%) (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Dyne Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Dyne Therapeutics, Inc. a real, registered company?
- Dyne Therapeutics, Inc. files with the SEC under CIK 1818794 (its SEC filings).
- Its shares are listed under the ticker DYN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under DYNE THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names JANUS HENDERSON GROUP Ltd. (filed 2026-08-13).
Who are Dyne Therapeutics, Inc.'s owners and officers?
Dyne Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-13 | Atlas Venture Fund Xi, L.P. | 2.4% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 7.3% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 6.8% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 7% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 18.7% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 8.3% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 5.4% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-03-06 | T. Rowe Price Investment Management, Inc. | 16.2% |
| Schedule 13G/A, 2026-02-17 | Janus Henderson Group PLC | 8.5% |
| Schedule 13G, 2026-01-08 | T. Rowe Price Investment Management, Inc. | 10.7% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 10.4% |
Questions about who owns Dyne Therapeutics, Inc.
Who owns Dyne Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Dyne Therapeutics, Inc.: T. Rowe Price Investment Management, Inc. (18.7%, Schedule 13G/A, filed 2026-05-15), Janus Henderson Group PLC (8.3%, Schedule 13G/A, filed 2026-05-15), Janus Henderson Group LTD. (7.3%, Schedule 13G/A, filed 2026-08-13), Blackrock, Inc. (7%, Schedule 13G/A, filed 2026-07-28) and Fmr LLC (6.8%, Schedule 13G/A, filed 2026-08-06).
Who are the largest shareholders of Dyne Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Dyne Therapeutics, Inc. on this page are T. Rowe Price Investment Management, Inc. (18.7%), Janus Henderson Group PLC (8.3%) and Janus Henderson Group LTD. (7.3%).
When did T. Rowe Price Investment Management, Inc. buy into Dyne Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G, filed 2026-01-08, reporting 10.7%; its latest, Schedule 13G/A filed 2026-05-15, reports 18.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Dyne Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dyne Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dyne Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Dyne Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,586,796 shares (1.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-07-29).
- , the chief executive and president: 429,507 shares (0.23% of shares outstanding), 357,507 held directly and 72,000 indirectly (Form 4, 2026-09-08).
- , a director: 428,946 shares (0.23% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-08-17).
- , the chief scientific officer: 195,840 shares (0.10% of shares outstanding) (Form 4, 2025-03-13).
- , the head of r and amp: 170,564 shares (0.09% of shares outstanding) (Form 4, 2026-10-22).
Shares outstanding: 187,386,963 as of 2026-10-30, from the company's latest SEC cover page.
How much has Dyne Therapeutics, Inc. raised?
No fundraising or offering filing from Dyne Therapeutics, Inc. is on file with us.
Keep reading
More on Dyne Therapeutics, Inc. and the records around it.
Dyne Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies: Korro Bio, Inc. (Aug 2026), Day One Biopharmaceuticals, Inc. (May 2026), SIONNA THERAPEUTICS, INC. (Oct 2025)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/dyne-therapeutics